Figure 3

AICD inhibits hNSC differentiation through miR-663. (a and b) Representative histograms (a) and quantification (b) of βIII-tubulin detection using flow cytometry in differentiated hNSCs transfected with AICD and control (green: βIII-tubulin; gray: isotype control). (c and d) Representative histograms (c) and quantification (d) of βIII-tubulin detection using flow cytometry in differentiated hNSCs transfected with miR-663 mimics and control (green: βIII-tubulin; gray: isotype control). (e and f) Representative images (e) and quantification (f) of βIII-tubulin detection using immunohistochemistry in differentiated hNSCs transfected with miR-663 mimics and control. Scale bar=200 μm. (g and h) Representative histograms (g) and quantification (h) of βIII-tubulin detection using flow cytometry in differentiated hNSCs transfected with control vector plus non-targeting control inhibitors (ctr In), AICD plus non-targeting control inhibitors, AICD plus miR-663 antisense inhibitors, respectively (green: βIII-tubulin; gray: isotype control). (i and j) Representative images (i) and quantification (j) of βIII-tubulin detection by immunohistochemistry in differentiated hNSCs transfected with control vector plus non-targeting control inhibitors (ctr In), AICD plus non-targeting control inhibitors, AICD plus miR-663 antisense inhibitors, respectively. Scale bar=200 μm. Quantification data were analyzed from at least three independent experiments (mean±S.E.M). *P<0.05; **P<0.01